Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cholesterol management stories

Nov 5, 2026

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 2026·2 sources
00
Nov 3, 2026

Amgen raises 2026 revenue forecast on strong cholesterol and cancer drug sales

Amgen raised its sales and profit forecast for the third time in 2026 after third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra and Uplizna.

Nov 3, 2026·2 sources
00
Nov 2, 2026

Novartis heart drug failure raises questions about genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.

Nov 2, 2026·2 sources
00
Jul 21, 2026

Nearly All US Heart Disease Deaths Linked to Modifiable Risk Factors, New Research Shows

A new study published in JAMA Cardiology reveals that approximately 90% of ischemic heart disease deaths in the United States remain attributable to modifiable risk factors including blood pressure, diet, and LDL cholesterol, despite significant declines in mortality since 1990. Research also shows these factors are linked to unstable coronary artery plaques that lead to heart attacks.

Jul 21, 2026·4 sources
00
Jul 16, 2026

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00
May 25, 2026

Eli Lilly's Gene-Editing Therapy Reduces Cholesterol by 62% in Early Clinical Trial

Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.

May 25, 2026·1 source
00

Top claims

  • ▪Novartis disclosed seven previously unreported cases of tumors in children treated with Zolgensma, a gene therapy for spinal muscular atrophy, as reported on November 6, 2026
  • ▪Amgen's Repatha was linked to a 20 percent reduction in heart attack risk beyond statin therapy in reported biopharma data on November 6, 2026
  • ▪Amgen's Repatha demonstrated fewer heart attacks beyond statin therapy in cardiovascular data reported on November 6, 2026

Subtopics

Drug Policy, Pricing & Approval4Clinical trials3Drug Approval and Clinical Trials3Cardiovascular diseases2Cardiovascular health.2Eli Lilly2Pharma2Biomarkers & bloodwork testing1Blood pressure management1Cancer & Oncology1Cancer and Cancer Treatment1Cancer treatment1Chicago1Clinical trial design1Clinical trial endpoints1Drug safety & pharmacovigilance1FDA drug approval1FDA drug approval process1Gene therapy1Heart health1New drug application (NDA) process1Pharmaceutical earnings1Pharmaceutical Industry1Preventive medicine1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories